Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter

This publication has 19 references indexed in Scilit:

• A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
  New England Journal of Medicine, 1996
• Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy
  Annals of Internal Medicine, 1995
• Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group
  Antimicrobial Agents and Chemotherapy, 1994
• Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection
  Annals of Internal Medicine, 1992
• Treatment of AIDS with combinations of antiretroviral agents
  The American Journal of Medicine, 1991
• Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions
  Journal of the American Statistical Association, 1989
• In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine
  Science, 1989
• The AIDS Dementia Complex
  The Journal of Infectious Diseases, 1988
• PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)
  The Lancet, 1988
• Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
  Proceedings of the National Academy of Sciences, 1986